Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)

NCT06346197 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT06346197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06346197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)
Lead sponsor
Centre Leon Berard
Phase
Phase 3
Overall status
Recruiting
Start date
December 8, 2025
Completion date
May 15, 2028
Enrollment
132 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, gastric cancer, metastatic cancer, msi-h